An interventional study of blood test and Lifestyle Evaluation in Cardio Vascular Disease and Risk Factor, Cardiovascular, sponsored by Hospital del Mar Research Institute (IMIM). Not yet recruiting. Open to female participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Hospital del Mar Research Institute (IMIM) · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Heart disease is the leading cause of death in women, yet it often goes undetected until it's too late. This project uses a simple clue found during routine breast cancer screenings-breast arterial calcification (BAC)-to spot early signs of heart risk in women aged 50 to 70. Those identified with BAC will be invited to take part in a personalized prevention program. This includes support to adopt healthier habits-like being more active, eating better, sleeping well, and managing stress-and regular checks of key health measures such as blood pressure and cholesterol. The study will compare two levels of care: a nurse-led program and a more intensive, app-supported version.
By turning mammograms into a dual-purpose tool for breast and heart health, this project empowers women with early action to reduce risk and improve long-term well-being.
Background and rationale Cardiovascular disease (CVD) is a leading cause of death in women, and cardiovascular risk is frequently underrecognized in this population. Breast arterial calcification (BAC), a form of medial vascular calcification visible on mammography, has been associated with increased cardiovascular risk. Because mammography is already performed in population-based breast cancer screening, BAC offers an opportunity to identify women who may benefit from cardiovascular prevention without additional imaging or radiation exposure. Artificial intelligence (AI) algorithms enable automated, scalable BAC detection within screening workflows.
Study design DUALMAMO combines two components: (1) AI-based detection of BAC in screening mammograms from Hostpital del Mar breast cancer screening program, and (2) a randomized controlled trial among eligible BAC-positive women, comparing a digital multicomponent lifestyle intervention with standard primary care advice. The study assesses whether this strategy improves cardiovascular risk factor control and, over longer follow-up, reduces major adverse cardiovascular events. Outcomes are detailed in the Outcome Measures section.
Procedures Women are eligible once their screening result is known. BAC-positive women are identified by the AI algorithm and invited by letter to participate through the study app/web platform. After informed consent, participants attend a baseline in-person visit (questionnaires, blood test, and clinical measurements) and are randomized through the app. A second in-person visit takes place at 6 months, with the blood test repeated if no recent result is available. Clinical events are followed up to 36 months through.
Implementation The trial also evaluates recruitment, retention, adherence, and cost-effectiveness to inform the potential integration of BAC-based cardiovascular risk identification into routine breast cancer screening.
Hospital del Mar Research Institute (IMIM) is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: blood test · Behavioral: Lifestyle Evaluation · Behavioral: Digital Cardiovascular Health Education and Personalized Physical Activity Program
Diagnostic Test: blood test · Behavioral: Lifestyle Evaluation · Behavioral: Usual Care Cardiovascular Counseling
A blood test to determine the following: -Colesterol total (mg/dL) * Colesterol LDL (mg/dL) * Colesterol HDL (mg/dL) * Triglicéridos (mg/dL) * Glucosa en ayunas (mg/dL) * Hemoglobina glicosilada (HbA1c, %) * Lp(a)
Cardiovascular risk factors questionnaire Patient Health Questionnaire-9 (PHQ-9) EuroQol 5-Dimension (EQ-5D) Chrononutrition Profile - Questionnaire (CP-Q) International Physical Activity Questionnaire (IPAQ)
Participants receive 6 months of access to a digital platform with structured educational modules on cardiovascular risk factors (sleep, diet, cholesterol, glucose, weight, physical activity, blood pressure, smoking and environmental factors), together with a personalized physical activity program. Participants also receive their baseline laboratory results review and the same information leaflet on breast arterial calcification (BAC) provided to the usual care arm. Allocation is by random assignment through the study application.
Participants receive personalized cardiovascular health advice reflecting routine primary care practice, together with written information on BAC and its cardiovascular significance.
Proportion of participants achieving cardiovascular risk control targets
LDL cholesterol \<100 mg/dL, blood pressure \<140/90 mmHg, and/or ≥20% reduction in cardiovascular risk
Time frame: 6 months
Change in depressive symptoms
PHQ-9
Time frame: 6 months
Change in health-related quality of life
EuroQol-5 (EQ-5D)
Time frame: 6 months
Change in physical activity
IPAQ
Time frame: 6 months
Change in crononutrition profile
Time frame: 6 months
No study locations are listed for this record.
Start is estimated for Dec 2026; primary completion for Jun 2027, 6 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital del Mar Research Institute (IMIM)